研究单位：[1]Capital Medical University[2]Xuanwu Hospital,Capital Medical University Beijing,Beijing,China,100053[3]Beijing Luhe Hospital,Capital Medical University Beijing,Beijing,China[4]The first Affiliated Hospital of Henan University of Science and Technology Luoyang,Henan,China[5]Nanyang Central Hospital Nanyang,Henan,China[6]Nanyang Second General Hospital Nanyang,Henan,China[7]First Affiliated Hospital of Zhengzhou University Zhengzhou,Henan,China[8]Henan Provincial People's Hospital Zhengzhou,Henan,China[9]The Third People's Hospital of Hubei Province Wuhan,Hubei,China[10]Hunan Provincial People's Hospital Changsha,Hunan,China
研究目的：
Currently, dual antiplatelet therapy with aspirin and clopidogrel (with loading doses) is widely used for patients with acute ischemic stroke. However, immediate, potent and reversible inhibition of platelet aggregation is not possible. Additionally, more than 5% patients have aspirin resistance and more than 15% patients have clopidogrel resistance. Therefore, an intravenously administered GPIIb/IIIa receptor inhibitor (Tirofiban) receptor blocker with fast onset and offset of actions will provide more desired antiplatelet effects in the setting of acute ischemic stroke, especially in patients with high risk of neurological deterioration. This study will measure the anti-platelet effects of Tirofiban in patients with acute ischemic stroke who had high risk of neurological deterioration.
